Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Stewart WF, Van Rooyen J, Cundiff G, Abrams P et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336. https://doi.org/10.1007/s00345-002-0301-4
2. Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14:849–855. https://doi.org/10.1007/s11136-004-0706-1
3. Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience: Persistence with antimuscarinic therapy in OAB. BJU Int 110:1767–1774. https://doi.org/10.1111/j.1464-410X.2012.11023.x
4. Duthie JB, Vincent M, Herbison GP et al (2011) Botulinum toxin injections for adults with overactive bladder syndrome. In: The cochrane database of systematic reviews. John Wiley & Sons, Ltd, Chichester. https://doi.org/10.1002/14651858.CD005493.pub3
5. Allergan (1989) Botox® (OnabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103000s5302lbl.pdf. Revised 6 2019. Accessed 6 2019
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献